Search results
Results From The WOW.Com Content Network
Occupation. Chairman of the Board of Directors of Novartis. Spouse. Married. Children. 2. Jörg Reinhardt (born 1956, Homburg, Saarland, Germany) has been Chairman of the Board of Directors of the Swiss pharmaceutical group Novartis AG since 2013. [1] [2] Since 2017, he has also been a member of the Board of Directors of the Swiss reinsurance ...
File:Novartis-Logo.svg. Size of this PNG preview of this SVG file: 512 × 84 pixels. Other resolutions: 320 × 53 pixels | 640 × 105 pixels | 1,024 × 168 pixels | 1,280 × 210 pixels | 2,560 × 420 pixels. Original file (SVG file, nominally 512 × 84 pixels, file size: 2 KB) This is a file from the Wikimedia Commons.
Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group and owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group. Novartis's businesses are divided into two operating divisions: Innovative Medicines and Sandoz (generics).
Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...
The transaction sent Roche shares to a record high. Novartis AG said on Thursday it would sell its nearly one-third voting stake in Roche back to its cross-town rival for $20.7 billion ...
The creators behind Hollywood’s latest and upcoming animated projects, including “Inside Out 2,” “Transformers One” and more, were celebrated at Variety‘s 10 Animators to Watch. The ...
Jimenez joined the board of directors at General Motors on June 9, 2015. Jimenez resigned from Novartis, leaving in February 2018, and was succeeded by Vasant Narasimhan. He joined the Board of Directors of San Francisco biotech startup uBiome in September 2018 and stepped down in April 2019 to start the biotech venture fund Aditum Bio.
A month's supply of Novo's diabetes drug Ozempic carries a list price of $935.77 in the U.S., while its obesity treatment Wegovy is priced at $1,349.02 per month, according to the drugmaker's ...